Effectiveness of the polysaccharide pneumococcal vaccine among HIV-infected persons in Brazil: A case control study

BMC Infectious Diseases

Volumn 7, Issue , 2007, Pages

  Veras, Maria Amelia S M ^a,b,c,d   Enanoria, Wayne T A ^a   Castilho, Euclides A ^b   Reingold, Arthur L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Medical Sciences School of Santa Casa of São Paulo   (Brazil)

^d Emilio Ribas Infectious Disease Hospital   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ADULT; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; BRAZIL; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENINGITIS; MULTIVARIATE ANALYSIS; RACE DIFFERENCE; SEROTYPING; STAPHYLOCOCCUS; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; CASE CONTROL STUDY; CLASSIFICATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MULTICENTER STUDY; REGRESSION ANALYSIS; RISK FACTOR; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ADULT; BRAZIL; CASE-CONTROL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MULTIVARIATE ANALYSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; REGRESSION ANALYSIS; RISK FACTORS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 37449029425     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-7-119     Document Type: Article

References (25)

1. Feikin DR Feldman C Schuchat A Janoff EN: Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis 2004, 4:445-55. 10.1016/S1473-3099(04)01060-6 15219555
2. Bartlett JG: Pneumonia in the patient with HIV infection. Infect Dis Clin North Am 1998, 12:807-20. xi 10.1016/S0891-5520(05)70211-7 9779391
3. Redd SC Rutherford GW 3rd Sande MA Lifson AR Hadley WK Facklam RR Spika JS: The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990, 162(5):1012-1017. 2230229
4. Janoff EN Breiman RF Daley CL Hopewell PC: Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologicperspectives. Ann Intern Med 1992, 117:314-24. 1637028
5. Flannery B Schrag S Bennett NM: Impact of childhood vaccination on racial disparities in invasive Streptococcuspneumoniae infections. JAMA 2004. 291:2197-203. 10.1001/jama.291.18.2197 15138241
6. Nuorti JP Butler JC Gelling L Kool JL Reingold AR Vugia DJ: Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000, 132:182-190. 10651598
7. CDC Prevention of Pneumococcal Disease: Recommendation of the Advisory Committee on Immunization Practices (ACIP) CDC 1997 2000.
8. Brazil: Recomendacao para vacinação em pessoas infectadas pelo HIV Brasilia: Ministry of Health 2001 2005
9. Broome CV Facklam RR Fraser DW: Pneumococcal disease after pneumococcal vaccination: An alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980, 303:549-52. 6995835
10. Butler JC Breiman RF Campbell JF Lipman HB Broome CV Facklam RR: Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993, 270:1826-31. 10.1001/jama.270.15.1826 8411526
11. Jackson L Neuzil KM Yu O Benson P Barlow WE Adams A: Effectiveness of Pneumococcal Polysaccharide Vaccine in OlderAdults. N Engl J Med 2003, 348:1747-55. 10.1056/NEJMoa022678 12724480
12. Dominguez A Salleras L Fedson DS Izquierdo C Ruíz L Ciruela P: Effectiveness od Pneumococcal Vaccination for Elderly People in Catalonia, Spain: A Case-control Study. Clin Inf Dis 2005, 40:1250-57. 10.1086/429236
13. Dworkin MS Ward JW Hanson DL Jones JL Kaplan EJ: Adult and Adolescent Spectrum of HIV Disease Project Pneumococcal disease among human immunodeficiency virus-infected persons: Incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001, 32(5):794-800. 10.1086/ 319218 11229848
14. Gebo KA Moore RD Keruly JC Chaisson RE: Risk factors for pneumococcal disease in human immunodeficiency virus-infectedpatients. J Infect Dis 1996, 173:857-62. 8603963
15. Guerrero M Kruger S Saitoh A: Aneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention. AIDS 1999, 13:1971-1975. 10.1097/00002030-199910010-00021 10513657
16. Breiman RF Keller DW Phelan MA: Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000, 160:2633-8. 10.1001/archinte.160.17.2633 10999977
17. Lindenburg CE Langendam MW Benthem BH Miedema F Coutinho RA: No evidence that vaccination with a polysaccharide pneumococcal vaccine protects drug users against all-cause pneumonia. AIDS 2001, 15:1315-7. 10.1097/ 00002030-200107060-00017 11426080
18. Hung C-C Chen M-Y Hsieh S-M Hsiao C-F Sheng W-H Chang S-C: Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: A prospective observational study. Vaccine 2004, 22:2006-2012. 10.1016/j.vaccine.2003.10.030 15121313
19. López-Palomo C Martin-Zamorano M Benítez E Fernández-Gutiérrez Guerrero F Rodríguez-Iglesias M Girón-González JA: Pneumonia in HIV-infected patients in the HAART era: Incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 2004, 72:517-524. 10.1002/jmv.20045 14981752
20. Grau I Pallares R Tubau F Schulze MH Llopis F Podzamczer D Linares J: Gudiol F for the Spanish Pneumococcal Infection Study Network Epidemiologic changes in bacteremic pneumococcal disease in patients with Human Immunodeficiency Virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005, 165:1533-1540. 10.1001/ archinte.165.13.1533 16009870
21. Barry PM Zetola N Keruly JC Moore RD Gebo KA Lucas GM: Invesive pneumococcal disease in a cohort of HIV-infected adults: Incidence and risk factors, 1990-2003. AIDS 2006, 20:437-444. 10.1097/ 01.aids.0000206507.54901.84 16439878
22. French N Nakiyingi J Carpenter LM: 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: Double-blind, randomised and placebo controlled trial. Lancet 2000, 355:2106-11. 10.1016/ S0140-6736(00)02377-1 10902624
23. Watera C Nakiyingi J Miiro G Muwonge R Whitworth JAG Gilks CF French N: 23-valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004, 18:1210-1213. 10.1097/00002030-200405210-00018 15166540
24. Walter A Orenstein RHB Dondero JT Hinman RA Marks SJ Bart KJ Sirotkin B: Field evaluation of vaccine efficacy. Bull World Hlth Org 1985, 63:1055-1067.
25. Moore RA Wiffen PJ Lipsky BA: Meta-analysis: Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Practice 2000, 1:1-10. 10.1186/1471-2296-1-1